News headlines about STRATA Skin Sciences (NASDAQ:SSKN) have been trending somewhat positive on Thursday, according to Accern Sentiment. Accern rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. STRATA Skin Sciences earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news coverage about the medical device company an impact score of 45.4964618902828 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

STRATA Skin Sciences traded down $0.09, hitting $1.98, during mid-day trading on Thursday, reports. 8,341 shares of the company’s stock traded hands, compared to its average volume of 165,515. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.15 and a quick ratio of 0.81. The firm has a market capitalization of $15.88 million, a P/E ratio of 0.99 and a beta of 0.75. STRATA Skin Sciences has a twelve month low of $1.06 and a twelve month high of $2.81.

STRATA Skin Sciences (NASDAQ:SSKN) last posted its quarterly earnings results on Monday, April 2nd. The medical device company reported ($0.10) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.27) by $1.17. The business had revenue of $8.60 million for the quarter, compared to the consensus estimate of $7.35 million. STRATA Skin Sciences had a negative return on equity of 36.19% and a negative net margin of 60.23%. analysts expect that STRATA Skin Sciences will post -0.23 EPS for the current year.

Several research analysts recently issued reports on the company. Zacks Investment Research raised STRATA Skin Sciences from a “hold” rating to a “strong-buy” rating and set a $2.00 target price on the stock in a research report on Tuesday, June 5th. HC Wainwright set a $3.00 target price on STRATA Skin Sciences and gave the company a “buy” rating in a research report on Thursday, May 31st. Finally, ValuEngine raised STRATA Skin Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st.

In other news, Director Samuel E. Navarro purchased 20,000 shares of the company’s stock in a transaction on Tuesday, June 5th. The shares were acquired at an average price of $2.01 per share, for a total transaction of $40,200.00. Following the purchase, the director now owns 7,000 shares in the company, valued at $14,070. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Luann Via purchased 25,000 shares of the company’s stock in a transaction on Friday, June 8th. The shares were purchased at an average price of $2.14 per share, for a total transaction of $53,500.00. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 48,000 shares of company stock worth $98,740. Company insiders own 9.95% of the company’s stock.

About STRATA Skin Sciences

STRATA Skin Sciences, Inc, a medical technology company, engages in developing and commercializing products for the treatment of dermatological disorders. Its products include XTRAC and VTRAC devices used for the treatment of psoriasis, vitiligo, and other skin disorders; and MelaFind system, an instrument for aiding dermatologists in the evaluation of clinically atypical pigmented skin lesions, when a dermatologist chooses to obtain additional information before making a final decision to biopsy in order to rule out melanoma.

Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with's FREE daily email newsletter.